Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients (NCT05653232)
Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From Hepatitis C Virus-Infected Donors to Uninfected Recipients: a Randomized Controlled Trial
🩺 Plain-English Summary (8th-Grade Level)
This study is being done to find out the best time to start medication for Hepatitis C Virus (HCV) in HCV-negative recipients of HCV-positive (HCV D+/R-) kidney transplants. Participants will be randomized into one of two groups: Arm 1 - Prophylaxis: This group will start the HCV medication before transplant and will take a shorter course of HCV medication for 2 weeks. Arm 2 - Transmit and Treat: This group will start the HCV medication after transplant and will take the full course (12 weeks) of HCV medication.
Who can join: Review the eligibility criteria below.
Location: University of California San Diego — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
- Prophylaxis (P2W) (OTHER)
- Transmit and Treat (T&T) (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- University of California San Diego — La Jolla, California
- Loma Linda University Health — Loma Linda, California
- Johns Hopkins University — Baltimore, Maryland
- NYU Langone Health — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- University of Utah Medical Center — Salt Lake City, Utah
- Virginia Commonwealth University — Richmond, Virginia
- University of Wisconsin, Madison — Madison, Wisconsin
📞 Contact the Study Coordinator
Phone: (410) 955-5684
Email: cdurand2@jhmi.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HCV
- Community Intervention to Eliminate HCV Among People Who Use Drugs. — Lyon, Auvergne-Rhône-Alpes
- Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada — Montreal, Quebec
Explore by condition: All HCV clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.